Boeing (BA) Tops Q3 EPS by 30c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Boeing (BA) Reports 3Q EPS Beat; Canaccord Genuity Reiterates Buy
October 22, 2015 10:27 AM EDTCanaccord Genuity reiterated a Buy rating and $165.00 price target on Boeing (NYSE: BA) following the company's 3Q15 earnings results. BA reported adjusted core EPS of $2.52 compared to the consensus estimates of $2.22.
Analyst Ken Herbert commented, "Boeing reported a better than expected Q3/15... More
RBC Capital Raises Price Target on Boeing (BA) Following 3Q15 EPS Beat
October 21, 2015 3:19 PM EDTRBC Capital reiterated a Sector Perform rating on Boeing (NYSE: BA), and raised the price target to $149.00 (from $145.00) following the company's 3Q15 earnings results. BA reported 'core' EPS of $2.52 coming in ahead of consensus at $2.21. Boeing defined 'core' EPS guidance was increased from... More
Wall St. declines; Valeant, healthcare weigh
October 21, 2015 7:08 AM EDTBy Caroline Valetkevitch
(Reuters) - U.S. stocks fell on Wednesday as a sharp drop in Valeant Pharmaceuticals hit the healthcare space, while the energy sector dropped along with oil prices.
Valeant Pharmaceuticals' (NYSE: VRX) U.S.-listed shares plunged to an intraday low of $88.50 on record volume after a short-seller accused the company of using specialty pharmacies to inflate its revenue.
The company denied the allegation, and later investor Bill Ackman said he increased his Valeant stake by about 2 million shares. The stock pared losses to end down 19.2 percent at $118.61,... More
